Roche presents data on Tecentriq progress at ESMO 2020

21 September 2020
2020_roche_big

Swiss drugmaker Roche (ROG: SIX) has presented detailed results from the Phase III IMpassion031 study of Tecentriq (atezolizumab), at the European Society for Medical Oncology (ESMO) virtual congress.

Adding to top-line results presented earlier in the year, the study tested a combination of the checkpoint blocker and chemotherapy in triple-negative breast cancer (TNBC).

The results show a statistically-significant and clinically-meaningful improvement, with pathological complete response (pCR) of 57.6%, compared with 41.1% in the placebo plus chemo group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology